Skip to main content

Regor Therapeutics Completes $90 Million Round for Novel Drugs

Regor Therapeutics of Shanghai completed a $90 million Series B financing that was led by Lilly Asia Ventures. Regor is a clinical stage biotech dedicated to developing clinically differentiated, best- and first-in-class drugs medicines to treat cancer, immune disorders and metabolic diseases. For drug discovery, the company uses its Computer Accelerated Rational Discovery (CARD) platform, which integrates structural biology, computational chemistry, therapeutic biology, medicinal chemistry and clinical development. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.